Back to mobile site

Stifel Reiterates Buy Rating on Insmed (INSM)

September 10, 2024 12:00 PM EDT Send to a Friend
Stifel analyst Stephen D. Willey reiterated a Buy rating and $88.00 price target on Insmed (NASDAQ: INSM)The analyst comments "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login